Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development
Open accessAbstract
The marine habitat has produced a significant number of very potent marine-derived agents that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of cases, in both in vivo murine models and in humans. Although many agents have entered clinical trials in cancer, to date, only Cytarabine, Yondelis® (ET743), Eribulin (a synthetic derivative based on the structure of halichondrin B), and the dolastatin 10 derivative, monomethylauristatin E (MMAE or vedotin) as a warhead, have been approved for use in humans (Adcetris®). In this review, we show the compounds derived from marine sources that are currently in clinical trials against cancer. We have included brief discussions of the approved agents, where they are in trials to extend their initial approved activity (a common practice once an agent is approved), and have also included an extensive discussion of the use of auristatin derivatives as warheads, plus an area that has rarely been covered, the use of marine-derived agents to ameliorate the pain from cancers in humans, and to act as an adjuvant in immunological therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A significant number of marine-derived metabolites act as antitumor agents via potent growth inhibition of human tumor cells both in vitro, in vivo (in murine) models and in cancer clinical trials.
“A significant number of marine-derived metabolites act as antitumor agents via potent growth inhibition of human tumor cells both in vitro, in vivo (in murine) models and in cancer clinical trials [13,17].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The influence of natural products upon drug discovery (Antiquity to late 1999)
Newman, D. J., Cragg, G. M., & Snader, K. M. (2000) · Natural Product Reports · doi:10.1039/a902202c · Cited by 1,293 · see citing works
Self-citationFrancisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R. L., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 932 · see citing works
Udwary, D., Allen, L. Z., Asolkar, R. N., Singan, V. R., Lapidus, A. L., Fenical, W., Jensen, P. R., & Moore, B. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700962104 · Cited by 537 · see citing works
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515 · see citing works
RINEHART, K. L. J., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F.-R., Li, L. H., & Martin, D. G. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a007 · Cited by 493 · see citing works
Bergmann (1951) · doi:10.1021/jo01146a023 · Cited by 403 · see citing works
Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
Cuevas, C., & Francesch, A. (2009) · Natural Product Reports · doi:10.1039/b808331m · Cited by 325 · see citing works
Discovery and development of the anticancer agent salinosporamide A (NPI-0052)
Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K., & Potts, B. C. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.075 · Cited by 291 · see citing works
Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata
Wright, A. E., Forleo, D. A., Gunawardana, G. P., Gunasekera, S. P., Koehn, F. E., & McConnell, O. J. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a006 · Cited by 268 · see citing works
THE ISOLATION OF A NEW THYMINE PENTOSIDE FROM SPONGES<sup>1</sup>
Bergmann, W., & Feeney, R. J. (1950) · Journal of the American Chemical Society · doi:10.1021/ja01162a543 · Cited by 267 · see citing works
Miles, D. W., Roche, H. H., Martín, M., Perren, T. J., Cameron, D., Glaspy, J. A., Dodwell, D., Parker, J., Mayordomo, J. I., Tres, A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0307 · Cited by 264 · see citing works
Anticancer Agents from Natural Products
Cragg, G. M. L., Kingston, D. G. I., & Newman, D. J. (2011) · CRC Press eBooks · doi:10.1201/b11185 · Cited by 257 · see citing works
Self-citationBoswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., Saad, O. M., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200212a · Cited by 209 · see citing works
On the origins and biosynthesis of tetrodotoxin
Chau, R., Kalaitzis, J. A., & Neilan, B. A. (2011) · Aquatic Toxicology · doi:10.1016/j.aquatox.2011.04.001 · Cited by 209 · see citing works
Rose, A. A. N., Grosset, A., Dong, Z., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1611 · Cited by 196 · see citing works
BERGMANN, W., & BURKE, D. C. (1955) · The Journal of Organic Chemistry · doi:10.1021/jo01128a007 · Cited by 194 · see citing works
Bacterial Biosynthesis and Maturation of the Didemnin Anti-cancer Agents
Xu, Y., Kersten, R. D., Nam, S., Lu, L., Al-Suwailem, A. M., Zheng, H., Fenical, W., Dorrestein, P. C., Moore, B. S., & Qian, P. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301735a · Cited by 185 · see citing works
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse, K. F., Jeffers, M., Pollack, V. A., McCabe, D. A., Shadish, M. L., Khramtsov, N. V., Hackett, C., Shenoy, S. G., Kuang, B., Boldog, F. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2018 · Cited by 183 · see citing works
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2012-07-444851 · Cited by 165 · see citing works
Leal, J., Martínez, M., García-Hernández, V., Moneo, V., Domingo, A., Bueren‐Calabuig, J. A., Negri, A., Gago, F., Guillen-Navarro, M. J., Avilés, P., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00945.x · Cited by 157 · see citing works
Tetrodotoxin (TTX) as a Therapeutic Agent for Pain
Nieto, F. R., Cobos, E. J., Tejada, M. A., Sánchez–Fernández, C., González‐Cano, R., & Cendán, C. M. (2012) · Marine Drugs · doi:10.3390/md10020281 · Cited by 155 · see citing works
Marine Antitumor Drugs: Status, Shortfalls and Strategies
Bhatnagar, I., & Kim, S. (2010) · Marine Drugs · doi:10.3390/md8102702 · Cited by 153 · see citing works
A New Antitumor Isoquinoline Alkaloid from the Marine Nudibranch Jorunna funebris
Fontana, A., Cavaliere, P., Wahidulla, S., et al. (2000) · Tetrahedron · doi:10.1016/s0040-4020(00)00629-3 · Cited by 141 · see citing works
Pharmacokinetic Considerations for Antibody Drug Conjugates
Lin, K., & Tibbitts, J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0800-y · Cited by 136 · see citing works
Ma, D., Hopf, C. E., Malewicz, A. D., Donovan, G. P., Senter, P. D., Goeckeler, W. F., Maddon, P. J., & Olson, W. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2107 · Cited by 133 · see citing works
The molecular mystique of tetrodotoxin
Moczydlowski, E. G. (2012) · Toxicon · doi:10.1016/j.toxicon.2012.11.026 · Cited by 122 · see citing works
Kahalalide Derivatives from the Indian Sacoglossan Mollusk Elysia grandifolia
Ashour, M., Edrada‐Ebel, R., Ebel, R., et al. (2006) · Journal of Natural Products · doi:10.1021/np060172v · Cited by 122 · see citing works
From micrograms to grams: scale-up synthesis of eribulin mesylate
Yu, M. J., Zheng, W., & Seletsky, B. M. (2013) · Natural Product Reports · doi:10.1039/c3np70051h · Cited by 121 · see citing works
Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer Compounds
Martín, M. J., Coello, L., Fernández, R., Reyes, F., Rodríguez, A., Murcia, C., Garranzo, M., Mateo, C., Sánchez-Sancho, F., Bueno, S., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja404578u · Cited by 114 · see citing works
Wang, X., Ma, D., Olson, W. C., & Heston, W. D. W. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0191 · Cited by 113 · see citing works
Immunotherapy in Bladder Cancer with Keyhole-Limpet Hemocyanin: A Randomized Study
Jurincic, C. D., Engelmann, U. H., Gasch, J., et al. (1988) · The Journal of Urology · doi:10.1016/s0022-5347(17)42610-3 · Cited by 110 · see citing works
Food-drugs from the sea : proceedings
Youngken, H. W., & Worthen, L. R. (1970) · Medical Entomology and Zoology · Cited by 108 · see citing works
von Schwarzenberg, K., & Vollmar, A. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.07.004 · Cited by 101 · see citing works
Didemnins, tamandarins and related natural products
Lee, J., Currano, J. N., Carroll, P. J., et al. (2012) · Natural Product Reports · doi:10.1039/c2np00065b · Cited by 90 · see citing works
Nguyen, H. H., Ma, G., Gladysheva, T. B., Fremgen, T., & Romo, D. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo101638r · Cited by 88 · see citing works
Brust, A., Palant, E., Croker, D. E., Colless, B., Drinkwater, R. D., Patterson, B., Schroeder, C. I., Wilson, D. T. R., Nielsen, C. K., Smith, M. T., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9003413 · Cited by 87 · see citing works
Li, D., Poon, K. A., Yu, S., Dere, R. C., Go, M., Lau, J., Zheng, B., Elkins, K., Danilenko, D. M., Kozak, K. R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1173 · Cited by 85 · see citing works
Jou, G., González, I., Alberício, F., Lloyd‐Williams, P., & Giralt, E. (1997) · The Journal of Organic Chemistry · doi:10.1021/jo961932h · Cited by 83 · see citing works
Soares, D. G., Machado, M. S., Rocca, C. J., Poindessous, V., Ouaret, D., Sarasin, A. R., Galmarini, C. M., Henriques, J. A. P., Escargueil, A. E., & Larsen, A. K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0252 · Cited by 81 · see citing works
Pollack, V. A., Álvarez, E., Tse, K. F., Torgov, M. Y., Xie, S., Shenoy, S. G., MacDougall, J. R., Arrol, S., Zhong, H., Gerwien, R. W., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0490-z · Cited by 80 · see citing works
Sapra, P., Damelin, M. I., DiJoseph, J. F., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0603 · Cited by 80 · see citing works
Microbial natural products: molecular blueprints for antitumor drugs
Giddings, L., & Newman, D. J. (2013) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-013-1331-1 · Cited by 78 · see citing works
Self-citationAntibody drug conjugates — Trojan horses in the war on cancer
Iyer, U. G., & Kadambi, V. J. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2011.07.005 · Cited by 76 · see citing works
Eustáquio, A. S., Nam, S., Penn, K., Lechner, A., Wilson, M. C., Fenical, W., Jensen, P. R., & Moore, B. S. (2010) · ChemBioChem · doi:10.1002/cbic.201000564 · Cited by 72 · see citing works
Inhibition of the Norepinephrine Transporter by the Venom Peptide χ-MrIA
Sharpe, I. A., Palant, E., Schroeder, C. I., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213030200 · Cited by 72 · see citing works
Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines
Martínez-Leal, J. F., García-Hernández, V., Moneo, V., Domingo, A., Bueren‐Calabuig, J. A., Negri, A., Gago, F., Guillen-Navarro, M. J., Avilés, P., Cuevas, C., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.003 · Cited by 71 · see citing works
Function-Oriented Biosynthesis of β-Lactone Proteasome Inhibitors in Salinispora tropica
Nett, M., Gulder, T. A. M., Kale, A. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901098m · Cited by 70 · see citing works
Romano, M., Frapolli, R., Zangarini, M., Bello, E., Porcu, L., Galmarini, C. M., García‐Fernández, L., Cuevas, C., Allavena, P., Erba, E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28213 · Cited by 63 · see citing works
Fang, F. G., Austad, B. C., Calkins, T. L., et al. (2013) · Synlett · doi:10.1055/s-0032-1318026 · Cited by 63 · see citing works
Pera, B., Barasoaı́n, I., Pantazopoulou, A., Canales, Á., Matesanz, R., Rodríguez‐Salarichs, J., García‐Fernández, L., Moneo, V., Jiménez‐Barbero, J., Galmarini, C. M., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400461j · Cited by 60 · see citing works
Synthesis of Tetrodotoxin, a Classic but Still Fascinating Natural Product
Nishikawa, T., & Isobe, M. (2013) · The Chemical Record · doi:10.1002/tcr.201200025 · Cited by 56 · see citing works
Brentuximab Vedotin: A CD 30‐Directed Antibody‐Cytotoxic Drug Conjugate
Newland, A. M., Li, J. X., Wasco, L. E., et al. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1170 · Cited by 54 · see citing works
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy
Zhou, L., LIU, F. Y., Li, Y., Peng, Y., LIU, Y. H., & LI, J. (2011) · Neoplasma · doi:10.4149/neo_2012_001 · Cited by 52 · see citing works
Lammers, R. J. M., Witjes, W. P. J., Janzing‐Pastors, M. H. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2936 · Cited by 47 · see citing works
Petit, K., & Biard, J.-F. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313040010 · Cited by 44 · see citing works
Shilabin, A. G., & Hamann, M. T. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.050 · Cited by 40 · see citing works
Hayashi, Y., Yamazaki‐Nakamura, Y., & Yakushiji, F. (2013) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c13-00404 · Cited by 39 · see citing works
Lechner, A., Eustáquio, A. S., Gulder, T. A. M., Hafner, M., & Moore, B. S. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.10.014 · Cited by 38 · see citing works
Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
Ansell, S. M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.542147 · Cited by 36 · see citing works
Discovery of E7389, a Fully Synthetic Macrocyclic Ketone Analog of Halichondrin B
Yu, M. J., Littlefield, B. A., & Kishi, Y. (2005) · CRC Press eBooks · doi:10.1201/9781420039658.ch13 · Cited by 36 · see citing works
Geoerger, B., Estlin, E. J., Aerts, I., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.036 · Cited by 33 · see citing works
Spinal actions of ω‐conotoxins, CVID , MVIIA and related peptides in a rat neuropathic pain model
Jayamanne, A., Jeong, H. J., Schroeder, C. I., Lewis, R. J., Christie, M. J., & Vaughan, C. W. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12251 · Cited by 30 · see citing works
Flahive, E. J., & Srirangam, J. K. (2005) · CRC Press eBooks · doi:10.1201/9781420039658.ch11 · Cited by 26 · see citing works
The application of genomic and molecular data in the treatment of chronic cancer pain
Turabi, A., & Plunkett, A. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.21707 · Cited by 23 · see citing works
Yap, T. A., Cortés-Funes, H., Shaw, H. S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.99 · Cited by 21 · see citing works
Massard, C., Margetts, J., Amellal, N., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9843-5 · Cited by 18 · see citing works
Yardley, D. A., Weaver, R. W., Melisko, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p6-10-01 · Cited by 17 · see citing works
Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma
Haddley, K. (2012) · Drugs of today · doi:10.1358/dot.2012.48.4.1788435 · Cited by 17 · see citing works
Martin, L. P., Krasner, C. N., Rutledge, T. L., et al. (2013) · Medical Oncology · doi:10.1007/s12032-013-0627-3 · Cited by 16 · see citing works
Conopeptides as novel options for pain management
Daly, N. L., & Craik, D. J. (2011) · Drugs of the Future · doi:10.1358/dof.2011.36.1.1561066 · Cited by 15 · see citing works
Chemical approaches to the discovery of new drugs.
Suckling, C. J. (1991) · PubMed · Cited by 14 · see citing works
Gordon, M. S., Gerber, D. E., Infante, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2507 · Cited by 14 · see citing works
Danila, D. C., Szmulewitz, R. Z., Higano, C. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.5020 · Cited by 14 · see citing works
Liu, J. F., Moore, K. N., Birrer, M. J., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-290 · Cited by 12 · see citing works
Martinez, S. L., Perez, L. N., Galmarini, C. M., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12331 · Cited by 9 · see citing works
Zhang, J., Gallery, M. A., Wyant, T. L., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr12 · Cited by 9 · see citing works
Capdevila, J., Clive, S., Casado, E., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2119-8 · Cited by 8 · see citing works
Sussman, D. R., Smith, L. M., Anderson, M. E., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-3962 · Cited by 6 · see citing works
Use of AGS-16M8F as a novel antibody drug conjugate (ADC) for treating renal cancers.
Gudas, J. M., Torgov, M. Y., An, Z., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e15014 · Cited by 6 · see citing works
Satpayev, D., Torgov, M. Y., Yang, P., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-2832 · Cited by 5 · see citing works
Astellas' Drug Discovery Strategy: Focus on Oncology
Yanagita, Y., & Takenaka, T. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys014 · Cited by 5 · see citing works
Veiby, P. O., Zhang, J., Yang, J., et al. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72127-5 · Cited by 4 · see citing works
Yang, P., Coleman, J. D., Li, Y., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-1274 · Cited by 3 · see citing works
Breij, E. C. W., Satijn, D. P. E., Verploegen, S. A. B. W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3066 · Cited by 3 · see citing works
Albertson, T., Sandalic, L., Law, C., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-2412 · Cited by 2 · see citing works
Takeda's Oncology Discovery Strategy
DeSchuytner, B., Kuvalanka, K., Hibner, B., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt023 · Cited by 2 · see citing works
Copeland, A., & Younes, A. (2010) · Drugs of the Future · doi:10.1358/dof.2010.35.10.1524349 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [21]Holt T.G. The Isolation and Structural Characterization of the Ecteinascidins Ph.D Thesis Department of Chemistry, University of Illinois at Urbana-Champaign Champaign, IL, USA 1986
- [52]Phillips A.C. Boghaert E.R. Vaidya K.S. Ansell P.J. Shalinsky D.R. Zhang Y. Voorbach M.J. Mudd S. Holen K.D. Humerickhouse R.A. ABT-414: An Anti-EGFR Antibody-Drug Conjugate as a Potential Therapeutic for the Treatment of Patients with Squamous Cell Tumors Proceedings of the 25th EORTC-NCI-AACR Symposium on Molecular Targets Cancer Therapeutics Boston, MA, USA 19–23 October 2013
Cited by
Sorted by citations
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works
“A significant number of marine-derived metabolites act as antitumor agents via potent growth inhibition of human tumor cells both in vitro, in vivo (in murine) models and in cancer clinical trials [13,17].”
Background
- Authors
- Newman, D., & Cragg, G.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- Corresponding author
- Newman, David
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2014-01-14
- Volume
- 12
- Issue
- 1
- Pages
- 255-278
- ISSN
- 1660-3397 (ISSN-L)
- PMC
- PMC3917273
- OpenAlex
- W2074296318
- Cited by
- 250
- References
- 87
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 8 · 2023: 17 · 2022: 18 · 2021: 23 · 2020: 35 · 2019: 10 · 2018: 20 · 2017: 29 · 2016: 36 · 2015: 32 · 2014: 11
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Marine Drugs (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
- Health Sciences › Medicine › Pharmacology › Microbial Natural Products and Biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Synthesis and Biological Activity
- Keywords
- marine-derived anticancer agents, cancer pain management, clinical trials, eribulin, trabectedin, dolastatin 10, monomethyl auristatin E, cytostatic agents, immunoadjuvant, tumor growth inhibition
- MeSH terms
- Animals, Antineoplastic Agents, Biological Products, Clinical Trials as Topic, Humans, Neoplasms, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
